Boston Startup Accelerators
Accelerator · Boston

Nucleate

Nonprofit accelerator empowering the next generation of biotech leaders. The equity-free Activator program supports PhDs, Masters students, and postdocs forming companies in human health and sustainability. Alumni have raised $310M+ in funding.

Visit nucleate.org → Boston, MA Accelerator Equity: No Healthcare / Biotech

At a glance

Type
Accelerator
Equity
No
Location
Boston, MA
Focus
Healthcare / Biotech
Website
nucleate.org

About Nucleate

Nonprofit accelerator empowering the next generation of biotech leaders. The equity-free Activator program supports PhDs, Masters students, and postdocs forming companies in human health and sustainability. Alumni have raised $310M+ in funding.

Nucleate is one of 20 startup accelerators, incubators and funding programs in TNT's Boston startup accelerators directory. It operates as a accelerator in Boston, MA and focuses on Healthcare / Biotech. MIT and Harvard founders can also compare campus-specific options in the MIT and Harvard programs guide.

Frequently asked questions

What is Nucleate?

Nucleate is a startup accelerator based in Boston, MA. Nonprofit accelerator empowering the next generation of biotech leaders. The equity-free Activator program supports PhDs, Masters students, and postdocs forming companies in human health and sustainability. Alumni have raised $310M+ in funding.

Does Nucleate take equity?

Nucleate lists its equity terms as: No.

What does Nucleate focus on?

Nucleate focuses on Healthcare / Biotech.

How does Nucleate compare to TNT?

TNT is Boston's pre-seed accelerator for MIT and Harvard founders, combining both schools in one cohort with $600K+ in partner credits and weekly founder mentorship. Many founders participate in more than one program; compare all 20 Boston options in TNT's directory.

Other Boston startup programs

Building at MIT or Harvard?

TNT is the pre-seed accelerator built for MIT and Harvard founders. First check, weekly founder mentorship, $600K+ in partner credits, and introductions to Boston investors.